Genmab A/S (GMAB.CO) is in Healthcare, Biotechnology, based in Denmark, listed on Copenhagen. Market cap 185.33B DKK. 52-week range 1,512.00 to 3,060.00 DKK. Trailing P/E 37.2. Data as of 2026-10-28.
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for ...